NCT06626971View on ClinicalTrials.gov

The Use of ARA290 for the Treatment of Diabetic Macular Oedema

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 12, 2017

Study Completion Date

August 31, 2017

Conditions
Diabetic Macular Oedema
Interventions
DRUG

ARA290

4 mg subcutaneous injections of ARA290 over an 84 day period

Trial Locations (1)

BT12 6BA

Belfast Health & Social Care Trust, Belfast

Sponsors
All Listed Sponsors
collaborator

Araim Pharmaceuticals, Inc.

INDUSTRY

lead

Belfast Health and Social Care Trust

OTHER

NCT06626971 - The Use of ARA290 for the Treatment of Diabetic Macular Oedema | Biotech Hunter | Biotech Hunter